TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving TherapyCambridge, Mass., October 30, 2019 — Thrombolytic Science, LLC (TSI) today announced progress with 10 patients enrolled in […]